Expression of Cdc7 and mcm2 as a marker for proliferation and prognosis in diffuse large B cell lymphoma

Yun Hou, Hua Qing Wang, Kai Fu, Hui Lai Zhang, Zheng Zi Qian, Li Hua Qiu, Wei Li, Shi Yong Zhou, Lan Fang Li, Xi Shan Hao

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: The aim of this study was to assess the expression of cell division cycle 7 (Cdc 7) kinase and minichromosome maintenance protein 2 (MCM2) in diffuse large B cell lymphoma (DLBCL) and explore their relationship with prognosis of DLBCL patients. Methods: Clinical data of 60 DLBCL patients treated in our hospital from 2008. 1 to 2010. 1 were collected. The expression levels of Cdc7 and MCM2 in peripheral blood and bone marrow were determined by real-time PCR. A statistical analysis was carried out to evaluate their association with prognosis in DLBCL patients. Results: The 2-year survival rate of patients with high expression of peripheral blood Cdc7 was 38. 3% and those with low expression 65. 4% (P=0. 001). The 2-year survival rate of patients with high expression of bone marrow Cdc7 was 37. 2% and those with low expression was 75. 5% (P = 0. 032). The 2-year survival rate of patients with high expression of MCM2 in peripheral blood was 44. 0% and those with low expression was 68. 2% (P = 0.025). The 2-year survival rate of patients with high expression of MCM2 in bone marrow was 39. 0% and those with low expression was 63. 4% (P = 0. 007). A poor disease specific survival was observed in DLBCL patients with high level expression of Cdc7 and MCM2. Conclusions: Cdc7 and MCM2 expression can be used to assess tumor proliferation and may be useful as an additional marker in combination with conventional markers in prediction of the outcome of DLBCL patients. Moreover, the Cdc7 and MCM2 signal pathway might be useful as a new approach in the treatment of refractory DLBCL lymphoma patients.

Original languageEnglish (US)
Pages (from-to)911-915
Number of pages5
JournalChinese Journal of Oncology
Volume33
Issue number12
DOIs
StatePublished - Dec 23 2011

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Minichromosome Maintenance Proteins
Survival Rate
Bone Marrow
Real-Time Polymerase Chain Reaction
Signal Transduction
Lymphoma
Cell Cycle
Phosphotransferases
Survival

Keywords

  • Cdc7
  • Lymphoma, non-hodgkin
  • MCM2
  • Prognosis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Expression of Cdc7 and mcm2 as a marker for proliferation and prognosis in diffuse large B cell lymphoma. / Hou, Yun; Wang, Hua Qing; Fu, Kai; Zhang, Hui Lai; Qian, Zheng Zi; Qiu, Li Hua; Li, Wei; Zhou, Shi Yong; Li, Lan Fang; Hao, Xi Shan.

In: Chinese Journal of Oncology, Vol. 33, No. 12, 23.12.2011, p. 911-915.

Research output: Contribution to journalArticle

Hou, Yun ; Wang, Hua Qing ; Fu, Kai ; Zhang, Hui Lai ; Qian, Zheng Zi ; Qiu, Li Hua ; Li, Wei ; Zhou, Shi Yong ; Li, Lan Fang ; Hao, Xi Shan. / Expression of Cdc7 and mcm2 as a marker for proliferation and prognosis in diffuse large B cell lymphoma. In: Chinese Journal of Oncology. 2011 ; Vol. 33, No. 12. pp. 911-915.
@article{1cb1bab2af1841dcbc6d32a863c700c1,
title = "Expression of Cdc7 and mcm2 as a marker for proliferation and prognosis in diffuse large B cell lymphoma",
abstract = "Objective: The aim of this study was to assess the expression of cell division cycle 7 (Cdc 7) kinase and minichromosome maintenance protein 2 (MCM2) in diffuse large B cell lymphoma (DLBCL) and explore their relationship with prognosis of DLBCL patients. Methods: Clinical data of 60 DLBCL patients treated in our hospital from 2008. 1 to 2010. 1 were collected. The expression levels of Cdc7 and MCM2 in peripheral blood and bone marrow were determined by real-time PCR. A statistical analysis was carried out to evaluate their association with prognosis in DLBCL patients. Results: The 2-year survival rate of patients with high expression of peripheral blood Cdc7 was 38. 3{\%} and those with low expression 65. 4{\%} (P=0. 001). The 2-year survival rate of patients with high expression of bone marrow Cdc7 was 37. 2{\%} and those with low expression was 75. 5{\%} (P = 0. 032). The 2-year survival rate of patients with high expression of MCM2 in peripheral blood was 44. 0{\%} and those with low expression was 68. 2{\%} (P = 0.025). The 2-year survival rate of patients with high expression of MCM2 in bone marrow was 39. 0{\%} and those with low expression was 63. 4{\%} (P = 0. 007). A poor disease specific survival was observed in DLBCL patients with high level expression of Cdc7 and MCM2. Conclusions: Cdc7 and MCM2 expression can be used to assess tumor proliferation and may be useful as an additional marker in combination with conventional markers in prediction of the outcome of DLBCL patients. Moreover, the Cdc7 and MCM2 signal pathway might be useful as a new approach in the treatment of refractory DLBCL lymphoma patients.",
keywords = "Cdc7, Lymphoma, non-hodgkin, MCM2, Prognosis",
author = "Yun Hou and Wang, {Hua Qing} and Kai Fu and Zhang, {Hui Lai} and Qian, {Zheng Zi} and Qiu, {Li Hua} and Wei Li and Zhou, {Shi Yong} and Li, {Lan Fang} and Hao, {Xi Shan}",
year = "2011",
month = "12",
day = "23",
doi = "10.3760/cma.j.issn.0253-3766.2011.12.007",
language = "English (US)",
volume = "33",
pages = "911--915",
journal = "Chinese Journal of Oncology",
issn = "0253-3766",
publisher = "Chinese Academy of Medical Sciences",
number = "12",

}

TY - JOUR

T1 - Expression of Cdc7 and mcm2 as a marker for proliferation and prognosis in diffuse large B cell lymphoma

AU - Hou, Yun

AU - Wang, Hua Qing

AU - Fu, Kai

AU - Zhang, Hui Lai

AU - Qian, Zheng Zi

AU - Qiu, Li Hua

AU - Li, Wei

AU - Zhou, Shi Yong

AU - Li, Lan Fang

AU - Hao, Xi Shan

PY - 2011/12/23

Y1 - 2011/12/23

N2 - Objective: The aim of this study was to assess the expression of cell division cycle 7 (Cdc 7) kinase and minichromosome maintenance protein 2 (MCM2) in diffuse large B cell lymphoma (DLBCL) and explore their relationship with prognosis of DLBCL patients. Methods: Clinical data of 60 DLBCL patients treated in our hospital from 2008. 1 to 2010. 1 were collected. The expression levels of Cdc7 and MCM2 in peripheral blood and bone marrow were determined by real-time PCR. A statistical analysis was carried out to evaluate their association with prognosis in DLBCL patients. Results: The 2-year survival rate of patients with high expression of peripheral blood Cdc7 was 38. 3% and those with low expression 65. 4% (P=0. 001). The 2-year survival rate of patients with high expression of bone marrow Cdc7 was 37. 2% and those with low expression was 75. 5% (P = 0. 032). The 2-year survival rate of patients with high expression of MCM2 in peripheral blood was 44. 0% and those with low expression was 68. 2% (P = 0.025). The 2-year survival rate of patients with high expression of MCM2 in bone marrow was 39. 0% and those with low expression was 63. 4% (P = 0. 007). A poor disease specific survival was observed in DLBCL patients with high level expression of Cdc7 and MCM2. Conclusions: Cdc7 and MCM2 expression can be used to assess tumor proliferation and may be useful as an additional marker in combination with conventional markers in prediction of the outcome of DLBCL patients. Moreover, the Cdc7 and MCM2 signal pathway might be useful as a new approach in the treatment of refractory DLBCL lymphoma patients.

AB - Objective: The aim of this study was to assess the expression of cell division cycle 7 (Cdc 7) kinase and minichromosome maintenance protein 2 (MCM2) in diffuse large B cell lymphoma (DLBCL) and explore their relationship with prognosis of DLBCL patients. Methods: Clinical data of 60 DLBCL patients treated in our hospital from 2008. 1 to 2010. 1 were collected. The expression levels of Cdc7 and MCM2 in peripheral blood and bone marrow were determined by real-time PCR. A statistical analysis was carried out to evaluate their association with prognosis in DLBCL patients. Results: The 2-year survival rate of patients with high expression of peripheral blood Cdc7 was 38. 3% and those with low expression 65. 4% (P=0. 001). The 2-year survival rate of patients with high expression of bone marrow Cdc7 was 37. 2% and those with low expression was 75. 5% (P = 0. 032). The 2-year survival rate of patients with high expression of MCM2 in peripheral blood was 44. 0% and those with low expression was 68. 2% (P = 0.025). The 2-year survival rate of patients with high expression of MCM2 in bone marrow was 39. 0% and those with low expression was 63. 4% (P = 0. 007). A poor disease specific survival was observed in DLBCL patients with high level expression of Cdc7 and MCM2. Conclusions: Cdc7 and MCM2 expression can be used to assess tumor proliferation and may be useful as an additional marker in combination with conventional markers in prediction of the outcome of DLBCL patients. Moreover, the Cdc7 and MCM2 signal pathway might be useful as a new approach in the treatment of refractory DLBCL lymphoma patients.

KW - Cdc7

KW - Lymphoma, non-hodgkin

KW - MCM2

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84862936263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862936263&partnerID=8YFLogxK

U2 - 10.3760/cma.j.issn.0253-3766.2011.12.007

DO - 10.3760/cma.j.issn.0253-3766.2011.12.007

M3 - Article

C2 - 22340100

AN - SCOPUS:84862936263

VL - 33

SP - 911

EP - 915

JO - Chinese Journal of Oncology

JF - Chinese Journal of Oncology

SN - 0253-3766

IS - 12

ER -